RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE

Quantum Genomics Stocks 2024

Quantum Genomics Stocks

34.85 M

Quantum Genomics Dividend yield

Ticker

ALQGC.PA

ISIN

FR0011648971

WKN

A1XAEB

In 2024, Quantum Genomics had 34.85 M outstanding stocks, a 0% change from the 34.85 M stocks in the previous year.

The Quantum Genomics Stocks history

YEARNUMBER OF STOCKS (undefined EUR)
2026e34.85
2025e34.85
2024e34.85
202334.85
202234.85
202127.44
202026.71
201918.06
201815.77
201710.99
20168.39
20156.93
20144.81
20134.11
20123.66
20113.4
20102.63
20092.21
2008-

Quantum Genomics Aktienanalyse

What does Quantum Genomics do?

Quantum Genomics SA is a French biotechnology company focused on the discovery and development of novel therapies for the treatment of cardiovascular diseases. The company was founded in 2005 in Grenoble, France, where its headquarters are still located. Over 25 employees are currently working on the development of new drugs. The business model of Quantum Genomics SA is based on the research and development of new and innovative solutions for the cardiovascular disease market. The company focuses on a new class of drugs that target the brain to lower blood pressure and treat certain cardiovascular diseases. The goal of these new therapies is to improve the effectiveness of existing treatment methods by directly addressing the causes of the disease. Quantum Genomics SA has established partnerships with renowned research institutes and universities. The collaboration with these institutions aims to accelerate and intensify the research and development of new drugs. Through this collaboration, the company will be able to develop new solutions and therapies to treat cardiovascular diseases at a faster pace. The company is currently working on two main products: Firibastat and the QT-Glutamylcyclotransferase inhibitor. Firibastat is an oral medication developed for the treatment of hypertension. The QT-Glutamylcyclotransferase inhibitor is another medication that is intended to lower blood pressure. These are promising new solutions that can enable Quantum Genomics SA to play a significant role in the cardiovascular disease market. The products of Quantum Genomics SA aim to treat cardiovascular diseases better and more effectively by directly targeting the brain. This aims to reduce the risk of serious complications and side effects that may occur with conventional medications. In recent years, Quantum Genomics SA has received several awards, including the "Innovation Prize" from the French government. These awards demonstrate that the company is on the right track and achieving its goals. Overall, Quantum Genomics SA has a promising business model based on the development of new therapies for the treatment of cardiovascular diseases. With collaborations with renowned research institutes and the development of promising new products, the company is well-positioned to be successful and make significant progress in the growing market of cardiovascular diseases. Quantum Genomics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Quantum Genomics's Shares Outstanding

Quantum Genomics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Quantum Genomics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Quantum Genomics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Quantum Genomics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Quantum Genomics Stock

How many stocks are there of Quantum Genomics?

The current number of stocks of Quantum Genomics is 34.85 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Quantum Genomics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Quantum Genomics evolved in recent years?

The number of shares of Quantum Genomics has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Quantum Genomics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Quantum Genomics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Quantum Genomics pay?

Over the past 12 months, Quantum Genomics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Quantum Genomics is expected to pay a dividend of 0 EUR.

What is the dividend yield of Quantum Genomics?

The current dividend yield of Quantum Genomics is .

When does Quantum Genomics pay dividends?

Quantum Genomics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Quantum Genomics?

Quantum Genomics paid dividends every year for the past 0 years.

What is the dividend of Quantum Genomics?

For the upcoming 12 months, dividends amounting to 0 EUR are expected. This corresponds to a dividend yield of 0 %.

In which sector is Quantum Genomics located?

Quantum Genomics is assigned to the 'Health' sector.

Wann musste ich die Aktien von Quantum Genomics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Quantum Genomics from 5/16/2024 amounting to 0 EUR, you needed to have the stock in your portfolio before the ex-date on 5/16/2024.

When did Quantum Genomics pay the last dividend?

The last dividend was paid out on 5/16/2024.

What was the dividend of Quantum Genomics in the year 2023?

In the year 2023, Quantum Genomics distributed 0 EUR as dividends.

In which currency does Quantum Genomics pay out the dividend?

The dividends of Quantum Genomics are distributed in EUR.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Quantum Genomics

Our stock analysis for Quantum Genomics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Quantum Genomics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.